Company Overview of Advanced Accelerator Applications S.A.
Advanced Accelerator Applications S.A., a radiopharmaceutical company, develops, produces, and commercializes molecular nuclear medicine (MNM) diagnostic and therapeutic products in France, Italy, Spain, Israel, Canada, the United States, and internationally. It provides positron emission tomography (PET) products, including Gluscan, a branded 18-fluorodeoxyglucose PET imaging agent that assists in the diagnosis of serious medical conditions primarily in oncology through assessing glucose metabolism; IASOflu, which images bone metastases; IASOdopa to diagnose Parkinson’s disease and tumors in various indications; and IASOcholine for diagnosing prostate cancer. The company also offers single-...
20 Rue Diesel
Saint Genis Pouilly, 01630
Founded in 2002
Key Executives for Advanced Accelerator Applications S.A.
Group Chief Financial Officer
Head of Clinical Development
Compensation as of Fiscal Year 2014.
Advanced Accelerator Applications S.A. Key Developments
Advanced Accelerator Applications S.A. Announces Earnings Results for the First Nine Months of 2014
Nov 20 14
Advanced Accelerator Applications S.A. announced earnings results for the first nine months of 2014. For the nine months, sales of EUR 50,156,000 compared to EUR 38,919,000 a year ago. Operating income was EUR 2,199,000 compared to EUR 1,373,000 a year ago. Net income from continuing operations was EUR 1,135,000 compared to loss of EUR 2,038,000 a year ago. Adjusted EBITDA was EUR 9,668,000 compared to EUR 7,643.000 a year ago. Net operating cash-flow was EUR 9 million, an increase of 33% compared to the 6.7 million a year ago.
Advanced Accelerator Applications SA Announces Earnings Results for the Full Year Ended December 31, 2013
Jul 10 14
Advanced Accelerator Applications SA announced earnings results for the full year ended December 31, 2013. For the period, the company reported net loss for the year from continuing operations of EUR 9,861,000 compared with EUR 16,912,000 for the same period a year ago. EBITDA was EUR 10,638,000 compared with EUR 6,577,000 for the same period a year ago. Sales for the year increased by 31.77% to EUR 53.8 million compared with EUR 40.8 million for the same period a year ago.
Advanced Accelerator Applications SA Appoints Kapil Dhingra as Independent Non-Executive Director
Apr 29 14
Advanced Accelerator Applications S.A. announced that Dr. Kapil Dhingra has joined the company Board of Directors as an Independent Non-Executive Director. Dr. Dhingra has over 25 year's experience in oncology clinical research and drug development, including nine years at Roche Pharmaceuticals, where he played a key role in the expansion of Roche Oncology. From 1999 to 2008 he served in positions of increasing responsibility at Roche, including Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to his time at Roche, Dr. Dhingra worked in the oncology clinical development group at Eli Lilly and Company. He has also previously served as a Clinical Instructor, Assistant Professor of Medicine at the University of Texas M.D. Anderson Cancer Center. Dr. Dhingra holds an M.B.,B.S. (equivalent to a U.S. M.D.) degree from the All India Institute of Medical Sciences. He is Board-certified in Internal Medicine and Medical Oncology.
Similar Private Companies By Industry
Recent Private Companies Transactions